Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 365 results for heart failure

  1. Thoracoscopically assisted mitral valve surgery (IPG245)

    Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).

  2. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  3. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  4. Dapagliflozin for treating chronic kidney disease (TA775)

    Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.

  5. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  6. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  7. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  8. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  9. Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.

  10. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

    This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.

  11. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  12. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  13. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued [GID-TA10179]

  14. Alteplase for treating acute ischaemic stroke (TA264)

    Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.